EAM Investors LLC Takes Position in Arcellx, Inc. (NASDAQ:ACLX)

EAM Investors LLC bought a new position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 43,009 shares of the company's stock, valued at approximately $3,298,000. EAM Investors LLC owned 0.08% of Arcellx as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ACLX. Headlands Technologies LLC purchased a new position in Arcellx in the 4th quarter worth about $41,000. KBC Group NV boosted its holdings in shares of Arcellx by 37.3% in the fourth quarter. KBC Group NV now owns 1,388 shares of the company's stock worth $106,000 after buying an additional 377 shares during the period. Avanza Fonder AB purchased a new position in shares of Arcellx in the fourth quarter worth approximately $184,000. Kazazian Asset Management LLC acquired a new stake in shares of Arcellx during the fourth quarter valued at approximately $204,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Arcellx in the 4th quarter valued at approximately $214,000. 96.03% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Kavita Patel sold 1,500 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $64.57, for a total transaction of $96,855.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher Heery sold 10,155 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $63.79, for a total transaction of $647,787.45. Following the completion of the sale, the insider now owns 37,486 shares of the company's stock, valued at approximately $2,391,231.94. The trade was a 21.32 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,455 shares of company stock worth $3,408,458. 6.24% of the stock is currently owned by company insiders.

Arcellx Price Performance

Arcellx stock traded up $1.96 during midday trading on Tuesday, reaching $62.89. The stock had a trading volume of 39,047 shares, compared to its average volume of 675,514. The firm's fifty day simple moving average is $64.84 and its two-hundred day simple moving average is $75.13. Arcellx, Inc. has a twelve month low of $47.88 and a twelve month high of $107.37. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -88.63 and a beta of 0.33.

Arcellx (NASDAQ:ACLX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.24). The business had revenue of $15.27 million during the quarter, compared to analyst estimates of $27.42 million. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. As a group, sell-side analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).